NEW YORK (GenomeWeb) – Goldman Sachs on Wednesday downgraded shares of Qiagen and Bruker to a Sell rating.

The investment bank also lowered its six-month price target for Qiagen to $19 from a prior target of $21 and the 12-month price target for Bruker to $15 from $21.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.